Scientists discover metformin's direct brain effects after 60 years of use

Metformin has been lowering blood sugar in diabetics for six decades, but doctors have never fully understood how. They knew it worked—that was never in question. What they didn't know was that the drug was doing something in the brain all along, something that researchers at Baylor College of Medicine have only now managed to see clearly.

The conventional story held that metformin did its work in the liver and the gut, places where it could suppress glucose production and reshape how the body processed food. It was a tidy explanation for a drug that had become one of the most prescribed medications in the world. But Dr. Makoto Fukuda and his team wondered whether the brain itself might be involved. The brain, after all, is the body's master regulator of glucose metabolism. Why wouldn't it play a role in how metformin worked?

They focused their attention on a specific region called the ventromedial hypothalamus and a protein within it called Rap1. When they gave metformin to genetically engineered mice that lacked Rap1 in this brain region, something unexpected happened: the drug stopped working. Blood sugar levels didn't improve. Other diabetes medications—insulin, GLP-1 agonists—still worked fine in these mice. Only metformin failed. This suggested that Rap1 wasn't just present when metformin worked; it was essential to the process.

Then came the striking part. The researchers injected metformin directly into the brains of diabetic mice in doses thousands of times smaller than what a person would swallow as a pill. The effect was dramatic. Blood sugar dropped significantly. The brain, it turned out, was exquisitely sensitive to the drug—far more sensitive than the liver or gut, which required much higher concentrations to respond. This sensitivity pointed to something the researchers had suspected: the brain wasn't just a bystander in metformin's action. It was a primary target.

Further investigation revealed which neurons were doing the work. In the ventromedial hypothalamus, cells marked by a protein called SF1 sprang to life when metformin arrived. These neurons became more electrically active, firing more readily. But only when Rap1 was present. In mice engineered to lack Rap1 in these specific neurons, metformin had no effect whatsoever. The chain of causation became clear: metformin suppresses Rap1, which allows SF1 neurons to activate, which then orchestrates a reduction in blood glucose.

The implications ripple outward. For sixty years, metformin has been prescribed as a liver and gut drug. Now it appears to have been working in the brain the entire time, through a pathway that medicine had never identified. This reframes how researchers might develop new diabetes treatments. Rather than focusing exclusively on peripheral organs, they could target this brain pathway directly, potentially creating drugs that work at even lower doses with fewer side effects.

Fukuda and his colleagues also noted that metformin has long been associated with other benefits—slowing brain aging, for instance—that have never been fully explained. The same Rap1 signaling pathway they've now identified might account for these effects as well. The next phase of their work will investigate whether this single mechanism in the brain explains not just metformin's glucose-lowering power, but its broader protective effects on the aging brain. A drug that has been in use for six decades may finally be revealing its deepest secrets.